Mirova Trims Position in Boston Scientific Co. (NYSE:BSX)

Mirova decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 9.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,102 shares of the medical equipment provider's stock after selling 2,661 shares during the quarter. Mirova's holdings in Boston Scientific were worth $2,242,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mechanics Bank Trust Department acquired a new position in shares of Boston Scientific in the 4th quarter valued at $415,000. Highland Capital Management LLC acquired a new position in Boston Scientific in the fourth quarter valued at $4,887,000. Covenant Asset Management LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth about $3,405,000. Brookstone Capital Management increased its position in shares of Boston Scientific by 23.7% during the fourth quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after purchasing an additional 20,307 shares in the last quarter. Finally, Beacon Investment Advisory Services Inc. lifted its holdings in shares of Boston Scientific by 31.7% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock valued at $1,744,000 after purchasing an additional 4,702 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of BSX stock traded up $2.21 during midday trading on Thursday, reaching $101.13. 8,984,425 shares of the company traded hands, compared to its average volume of 6,413,447. The firm has a market cap of $149.58 billion, a PE ratio of 80.90, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The firm's 50 day simple moving average is $98.85 and its two-hundred day simple moving average is $94.58. Boston Scientific Co. has a 1-year low of $70.97 and a 1-year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. On average, equities research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BSX. Stifel Nicolaus raised their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Royal Bank of Canada upped their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday. Wells Fargo & Company raised their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Citigroup lifted their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Finally, BTIG Research reissued a "buy" rating on shares of Boston Scientific in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $112.87.

Insider Buying and Selling at Boston Scientific

In related news, CFO Daniel J. Brennan sold 15,087 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the sale, the chief financial officer now owns 241,451 shares of the company's stock, valued at $25,369,256.57. This trade represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 1,201 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the completion of the transaction, the executive vice president now directly owns 25,443 shares of the company's stock, valued at $2,704,845.33. The trade was a 4.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 138,009 shares of company stock worth $14,407,381. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.